Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, specializing in cancer detection, diagnosis, and treatment guidance through advanced genomic testing. The company develops and delivers multi-cancer early detection tests, hereditary cancer risk assessment panels, and oncology genomic profiling solutions. Primary product lines include Cologuard (at-home colorectal cancer screening utilizing stool-based DNA testing), Oncotype DX (tissue-based genomic assays for breast, colon, and prostate cancers providing recurrence risk scores and treatment recommendations), and other specialized genomic tests. Exact Sciences operates state-of-the-art CLIA-certified laboratories and conducts rigorous clinical validation studies published in peer-reviewed journals. The company serves patients, healthcare providers, oncologists, and researchers globally, with a focus on enabling informed clinical decision-making through precision medicine. Recently acquired by Abbott, Exact Sciences maintains strong regulatory credentials including FDA clearances for its key diagnostic assays. The company emphasizes collaboration with top medical institutions, advocacy organizations, and policymakers to expand access to genomic cancer testing and improve early detection rates across diverse populations.